Skip to content

Share

  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page
CLIENT STORY

Best practice inhaler development

PA has a proven track record of delivering inhalation solutions from concept right through to launch and can provide you with all the support you need to achieve the best possible development programme.

 

The market for inhaled therapies continues to grow. Sales of asthma/COPD products alone are expected to be $23 billion by 2018*. With many drugs for treatment of other conditions also being considered for delivery by inhalation the respiratory market remains an attractive proposition.

But the realisation of a successful inhaler is an immensely complex task. For example, selecting the right technical approach for your drug, and the decision to either design your own device or to source a third party will have a major impact on project success. Also, sub-optimal product testing during development and in manufacturing can drive costs up and cause substantial programme delays. Lack of a robust manufacturing strategy can further delay the launch of your product.

How can the pitfalls of inhaler development be avoided and best practice be achieved?

PA Consulting Group has a proven track record of delivering inhalation solutions from concept right through to launch and can provide you with all the support you need to achieve the best possible development programme. With more than 25 years of experience of product and process development in the pharmaceutical sector, we remain at the forefront of technological innovation in the field of inhalatory medicine.

* Datamonitor Commercial Insight: Asthma & COPD – On the verge of generic entry, June 2009


For a major pharmaceutical company, PA was responsible for the design and development of a novel breath actuated inhaler.

PA has undertaken a State of the Art review of dose counter mechanisms within the inhalation market.

For a major US pharmaceutical  company, PA developed a highly accurate product testing system to automate a manual Emitted Dose Test.

Following the success of its respiratory drug delivery technology platform a       US-based inhalation technology company asked PA to advise on its strategy for the next 10 years.

PA worked with a pharmaceutical client new to medical devices to manage the quality and development project for its pulmonary device.


To find out more about our drug delivery strategy and product development services, please contact us now.

×

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.